Formation Bio Licenses Gusacitinib to Sanofi for Novel Indication Study
US-based AI-native pharma company Formation Bio announced the licensing of gusacitinib, an oral dual JAK/SYK...
Novo Nordisk’s Ozempic Gets Positive CHMP Opinion for Peripheral Artery Disease
Denmark-based Novo Nordisk A/S (NYSE: NVO) announced that the European Medicines Agency’s (EMA) Committee for...
Illumina to Acquire SomaLogic for $350M to Expand Proteomics Tech Integration
US major Illumina (NASDAQ: ILMN) announced plans to acquire SomaLogic, a leader in data-driven proteomics...
Denovo Biopharma Inks Licensing Deal With Chuang Yi for DB104 in Taiwan
Denovo Biopharma, a US-headquartered precision medicine company with significant operations in China, announced a licensing...
Hengrui Pharmaceuticals Wins NMPA Approval for Six Novel Solid Tumor Drugs
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving clinical trial approvals from the...
Gan & Lee Pharmaceuticals Presents Phase II Results of GZR18 and GZR4 at ADA Scientific Sessions
China-based Gan & Lee Pharmaceuticals (SHA: 603087) presented multiple Phase II clinical outcomes for its...
EMA Panel Recommends Bio-Thera’s Usymro for Autoimmune Diseases
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA)...
J&J’s Darzalex SC Recommended by CHMP for High-Risk Smoldering Multiple Myeloma
The European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended...
Eli Lilly’s Efsitora Meets Key Endpoints in Phase III Trials for Type 2 Diabetes
US major Eli Lilly and Company (NYSE: LLY) presented detailed results from the Phase III...
Johnson & Johnson’s Imbruvica Secures CHMP Recommendation for Expanded MCL Use
US giant Johnson & Johnson (J&J, NYSE: JNJ) announced that the Committee for Medicinal Products...
Bayer’s Nubeqa Receives Positive CHMP Opinion for mHSPC Treatment
German pharmaceutical giant Bayer AG (ETR: BAYN) announced last week that the European Medicines Agency...
Boao Lecheng Partners with China National Center for Neurological Diseases to Establish Translational Center
The Boao Lecheng International Medical Tourism Pilot Zone Administration announced last week a strategic cooperation...
Sichuan Huiyu’s CDCP1-Targeted ADC HY0001a Gets NMPA Clinical Trial Approval
China-based Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553) announced that it has received clinical trial...
Changshan Biochemical Receives NMPA Clearance for Albenatide in Weight Loss Trials
China’s Hebei Changshan Biochemical Pharmaceutical Co., Ltd (CSBIO; SHE: 300255) announced that it has received...
ImmuneOnco Receives NMPA Approval for IMC-003/IMM72 in Pulmonary Arterial Hypertension Trial
China-based ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) announced that it has received clinical trial...
United Imaging Intelligence Closes RMB 1B Series A Round to Boost AI in Healthcare
United Imaging Intelligence, the AI-focused subsidiary of Shanghai United Imaging Healthcare Co., Ltd., reportedly secured...
MGI Tech’s DNBSEQ-T1+ Gains CE IVDR Certification for EU Market Entry
China-based gene sequencing specialist MGI Tech Co., Ltd (SHA: 688114) announced that its latest mid-throughput...
Jiangxi Rimag to Acquire 70% Stake in Guangzhou Gaomai for RMB 54 Million
China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) is set to acquire a 70% stake...
Simcere Pharma’s Quviviq Receives NMPA Approval for Insomnia Treatment
Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) revealed that its marketing approval filing for Quviviq...
Sanofi and Regeneron Win FDA Approval for Dupixent in Bullous Pemphigoid Treatment
France major Sanofi (NASDAQ: SNY) and US-based biopharma Regeneron (NASDAQ: REGN) announced that Dupixent (dupilumab)...